Apolipoprotein E and Alzheimer disease

pathobiology and targeting strategies

Research output: Contribution to journalReview article

Abstract

Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.

Original languageEnglish (US)
Pages (from-to)501-518
Number of pages18
JournalNature Reviews Neurology
Volume15
Issue number9
DOIs
StatePublished - Sep 1 2019

Fingerprint

Apolipoproteins E
Alzheimer Disease
Apolipoprotein E4
Alleles
Pathology
Amyloid
Apolipoprotein E2
Apolipoprotein E3
Precision Medicine
Neuronal Plasticity
Brain
Research
Protein Isoforms
Lipids
Glucose
Genes

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

Apolipoprotein E and Alzheimer disease : pathobiology and targeting strategies. / Yamazaki, Yu; Zhao, Na; Caulfield, Thomas; Liu, Chia-Chen; Bu, Guojun D.

In: Nature Reviews Neurology, Vol. 15, No. 9, 01.09.2019, p. 501-518.

Research output: Contribution to journalReview article

@article{c0fa8f03e99b43df912c0c329f5e155b,
title = "Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies",
abstract = "Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.",
author = "Yu Yamazaki and Na Zhao and Thomas Caulfield and Chia-Chen Liu and Bu, {Guojun D}",
year = "2019",
month = "9",
day = "1",
doi = "10.1038/s41582-019-0228-7",
language = "English (US)",
volume = "15",
pages = "501--518",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Apolipoprotein E and Alzheimer disease

T2 - pathobiology and targeting strategies

AU - Yamazaki, Yu

AU - Zhao, Na

AU - Caulfield, Thomas

AU - Liu, Chia-Chen

AU - Bu, Guojun D

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.

AB - Polymorphism in the apolipoprotein E (APOE) gene is a major genetic risk determinant of late-onset Alzheimer disease (AD), with the APOE*ε4 allele conferring an increased risk and the APOE*ε2 allele conferring a decreased risk relative to the common APOE*ε3 allele. Strong evidence from clinical and basic research suggests that a major pathway by which APOE4 increases the risk of AD is by driving earlier and more abundant amyloid pathology in the brains of APOE*ε4 carriers. The number of amyloid-β (Aβ)-dependent and Aβ-independent pathways that are known to be differentially modulated by APOE isoforms is increasing. For example, evidence is accumulating that APOE influences tau pathology, tau-mediated neurodegeneration and microglial responses to AD-related pathologies. In addition, APOE4 is either pathogenic or shows reduced efficiency in multiple brain homeostatic pathways, including lipid transport, synaptic integrity and plasticity, glucose metabolism and cerebrovascular function. Here, we review the recent progress in clinical and basic research into the role of APOE in AD pathogenesis. We also discuss how APOE can be targeted for AD therapy using a precision medicine approach.

UR - http://www.scopus.com/inward/record.url?scp=85069964621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069964621&partnerID=8YFLogxK

U2 - 10.1038/s41582-019-0228-7

DO - 10.1038/s41582-019-0228-7

M3 - Review article

VL - 15

SP - 501

EP - 518

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

IS - 9

ER -